[
    {
        "id": "osp-12316",
        "type": "article-journal",
        "title": "Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia",
        "author": [
            {
                "family": "Nuruddin",
                "given": "Murtuza"
            },
            {
                "family": "Roy",
                "given": "Soma Rani"
            },
            {
                "family": "Hoque",
                "given": "Fahmida"
            }
        ],
        "URL": "https://omanscience.com/en/articles/pegylated-interferon-alpha-2a-for-the-treatment-of-ocular-surface-squamous-neoplasia",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2022
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "15",
        "issue": "1",
        "page": "81-84",
        "DOI": "10.4103/ojo.ojo_146_21",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN."
    }
]